GLAUKOS Corp
About GLAUKOS Corp
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $507.4M
- Net income
- -$187.7M
- Total assets
- $893.5M
- Market cap
- $7.3B
- Gross margin
- 55.7%
- Operating margin
- -39.3%
- Net margin
- -37.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $507.4M
- Cost of revenue
- $111.8M
- Gross profit
- $282.8M
- Operating expenses
- $482.4M
- Operating income
- -$199.6M
- Income tax
- -$5.4M
- Net income
- -$187.7M
- EPS (basic)
- $-3.28
- EPS (diluted)
- $-3.28
Balance sheet
- Total assets
- $893.5M
- Current assets
- $475.0M
- Total liabilities
- $237.3M
- Current liabilities
- $101.3M
- Shareholders’ equity
- $656.2M
Cash flow
- Operating cash flow
- -$14.8M
- Investing cash flow
- -$77.6M
- Financing cash flow
- $11.9M
- Net cash flow
- -$80.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $7.3B
- EPS (diluted)
- $-3.28
- Shares outstanding
- 60.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 25, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $187.7M in FY2025.
- Revenue grew 73% from FY2021 to FY2025.
- Gross margin of 55.7%, net margin -37.0%.
- Trading 15% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GLAUKOS Corp.
Write a review
News about GLAUKOS Corp
News & sentiment via Polygon.io
